In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and may be eligible to receive a 180 ...
Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to ...
Lupin receives US FDA tentative approval for raltegravir tablets, USP: Our Bureau, Mumbai Friday, November 8, 2024, 17:45 Hrs [IST] Global pharma major Lupin Limited (Lupin) annou ...